

Klaus Schmierer, MB BS PhD FRCP

Klaus Schmierer is a Reader in Neurology at The Blizard Institute, Barts and The London School of Medicine & Dentistry (Queen Mary University of London), and a Consultant Neurologist at The Royal London Hospital of Barts Health NHS Trust, where he is both the Research Lead for Neurology and Clinical Lead for BartsMS.

He serves on the Consortium for Progressive MS of the MS Society's Clinical Trials Network, and the Advisory Board of the UK MS Register. He is also the Lead for MS at the National Institute of Health Research (NIHR) North Thames Clinical Research Network. Dr Schmierer has been an advisor to the EMA, MHRA, and NICE on new drugs for MS.

Ever since starting his career in neurology, Dr Schmierer has maintained a clinical and experimental research focus on MS. His work includes research into the pathology, pathophysiology, MRI appearance and disease control in people with MS, the (differential) diagnosis & monitoring of MS, and investigator-led and commercial clinical trials. He advocates a pro-active treatment approach at all stages of MS.

Dr Schmierer is the Chief Investigator of #ChariotMS, the first ever disease modifying treatment trial focussing on people with advanced MS who have an EDSS of ≥ 6.5 . This UK-wide multi-centre trial is supported by the NIHR (Efficacy and Mechanisms Evaluation), the MS Society UK, the US National MS Society and Merck Healthcare, and will start recruitment in late 2019.

Follow Dr Schmierer on Twitter @KlausSchmierer

<http://www.researchpublications.qmul.ac.uk/publications/staff/25616.html>

<https://multiple-sclerosis-research.org/>